BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
T. Reislander, E. Puig Lombardi, F. J. Groelly, A. Miar, M. Porru, B. Wright, H. Lockstone, A. Biroccio, A. Harris, A. Londono, M. Tarsounas
This study shows that BRCA2 loss in cancer cells triggers innate immune responses, which are enhanced by PARP inhibitors, suggesting a mechanism for their therapeutic effect.
bioRxiv · Dec 10, 2018Cancer Biology